Health ❯ Healthcare ❯ Patient Care ❯ Chronic Illness Management

Quality of Life

FDA Approves Juvmo as First D1/D5 Agonist for Parkinson’s Disease

The drug’s D1/D5 mechanism could slow patients’ need to raise levodopa doses, with U.S. availability scheduled for October 2026.

Novartis’ Del‑Desiran Misses Phase III and Triggers Large Share Selloff